CorMedix (CRMD)
(Delayed Data from NSDQ)
$7.50 USD
+0.20 (2.74%)
Updated Sep 24, 2024 03:59 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CRMD 7.50 +0.20(2.74%)
Will CRMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRMD
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade
Other News for CRMD
CorMedix Inc. Announces New Commercial Agreement
CorMedix announces new commercial agreement
CorMedix Inc. to Present at the Cantor Global Healthcare Conference
Biotech Alert: Searches spiking for these stocks today
CorMedix Inc. Announces New Commercial Agreement